Intuitive Surgical posted Q2 results above consensus with EPS of $2.80 on $2.89B revenue, beating estimates of $2.50 and $2.82B. Management highlighted strength across da Vinci, Ion, and growing digital solutions. Despite the beat, ISRG slid about 8.5% in extended trading, suggesting investors are focused on outlook and margin guidance rather than current-quarter results.
Intuitive Surgical (ISRG) exhibited strong earnings that indicate continued growth potential. The rising adoption of robotic surgery systems suggests an increase in surgical procedures over the coming quarters, positively impacting ISRG's revenue outlook.
Intuitive Surgical exceeded revenue and earnings expectations for Q4. However, the anticipated growth rate for da Vinci procedures is slowing down, with analysts adjusting price targets reflecting mixed sentiment.
Intuitive Surgical's strong Q4 2025 results feature better-than-expected EPS and revenue growth, driven by an increase in da Vinci procedures. However, the 2026 guidance suggests a slight slowdown, which may impact investor sentiment despite strong cash flow and share repurchases.
Intuitive Surgical's Q4 2025 results surpassed expectations, driven by robust demand for its surgical robots, leading to a significant stock surge. This positive momentum signals potential for continued market growth and investor confidence in the company's future performance.
Intuitive Surgical reported strong Q4 results, surpassing Wall Street profit and revenue expectations, driven by increasing demand for its surgical robots. This performance indicates robust growth potential in the minimally invasive procedures market, likely enhancing future investor confidence and stock performance.